Lincoln Pharmaceuticals · NSE: LINCOLN · BSE: 531633
Q3 FY22 results · Oct–Dec 2021
Lincoln Pharmaceuticals reported revenue from operations of ₹119.88 crore (up 6.9% from Q3 FY21) and net profit of ₹17.60 crore (up 31.7% from Q3 FY21) for Q3 FY22 (Oct–Dec 2021), on a standalone basis.
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 119.88 | 112.19 | +6.9% | 125.64 | −4.6% |
| Other income | 2.64 | 1.06 | +147.5% | 3.77 | −30.1% |
| Total income | 122.52 | 113.26 | +8.2% | 129.41 | −5.3% |
| Profit before tax | 23.60 | 18.16 | +30.0% | 30.24 | −21.9% |
| Net profit for the period | 17.60 | 13.37 | +31.7% | 22.88 | −23.1% |
| EPS, basic (₹) | 8.79 | 6.68 | +31.5% | 11.44 | −23.2% |
| Net margin (%) | 14.7 | 11.9 | 18.2 |
Standalone
- Filed with BSE
- 11 Feb 2022, 17:04 IST
- Board meeting
- 10 Feb 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE